Catch up with our insights on the big issues in pharma.
Our thought leadership library brings you our latest data-driven reports, infographics and articles that tackle the big issues, interesting niches and everything in between.
ASCO 2026 data underscores a shift in how oncology assets are evaluated, with increasing focus on durability, tolerability, and real-world differentiation alongside efficacy.
These factors are becoming central to both commerci...
Antibody‑drug conjugates continue to draw sustained attention from dealmakers. The category combines clinical validation with ongoing technical flexibility, creating multiple paths to differentiation across...
Q2 2026 is set to be one of the most catalyst-heavy quarters in recent biotech history, with activity dominated by trial updates, topline data, and regulatory decisions that together account for over 70%...
Supporting Cross-Functional Teams with Corporate-Level Competitive Intelligence
Competitive intelligence in biopharma is typically strong at the asset and indication level but often fragmented at the...
Biopharma entered 2026 with cautious optimism. Where do we stand at the end of the first quarter?
M&A accelerated sharply in March. IPO activity gathered pace before pausing again. Venture capital held steady,...
Loss of exclusivity is accelerating disruption across pharma, putting billions in revenue at risk and testing the limits of traditional forecasting.
As patent cliffs approach, forecasting teams must model not just dec...
